AKAO 2017 Annual Report

105 Achaogen, Inc. Consolidated Statements of Operations (in thousands except for share and per share amounts) Year Ended December 31, 2017 2016 2015 Contract revenue..................................................................... $ 11,175 $ 41,773 $ 26,061 Operating expenses Research and development................................................ 95,598 73,999 40,228 General and administrative................................................ 41,903 17,122 12,406 Total operating expenses ........................................................ 137,501 91,121 52,634 Loss from operations .............................................................. (126,326) (49,348) (26,573) Interest expense ...................................................................... (2,855) (2,320) (699) Change in warrant and derivative liabilities ........................... 1,928 (19,859) (19) Other income, net.................................................................... 1,635 300 198 Net loss ................................................................................... $ (125,618) $ (71,227) $ (27,093) Basic and diluted net loss per common share......................... $ (3.17) $ (3.00) $ (1.49) Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share .......... 39,645,635 23,707,063 18,147,986 See accompanying notes to consolidated financial statements.